Absci is trading 7.25% down at $8.57 as U.S. equities sell off, with the Nasdaq Composite down 1.49% and the S&P 500 down 0.67%.

  • No new company-specific announcement dated August 18, 2026 was found; investors may be reassessing the August 11 earnings release, which showed $0.3 million revenue, a $33.2 million net loss, and an after-hours reaction to the results.
  • Positive ABS-201 data and Lilly-backed $100 million financing remain recent supportive developments, but neither directly explains the August 18 decline.